Department of Clinical Laboratory, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430077, China.
Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
Mini Rev Med Chem. 2019;19(19):1611-1626. doi: 10.2174/1389557519666190903115424.
Over the past three decades, the knowledge gained about the mechanisms that underpin the potential use of Rhodiola in stress- and ageing-associated disorders has increased, and provided a universal framework for studies that focused on the use of Rhodiola in preventing or curing metabolic diseases. Of particular interest is the emerging role of Rhodiola in the maintenance of energy homeostasis. Moreover, over the last two decades, great efforts have been undertaken to unravel the underlying mechanisms of action of Rhodiola in the treatment of metabolic disorders. Extracts of Rhodiola and salidroside, the most abundant active compound in Rhodiola, are suggested to provide a beneficial effect in mental, behavioral, and metabolic disorders. Both in vivo and ex vivo studies, Rhodiola extracts and salidroside ameliorate metabolic disorders when administered acutely or prior to experimental injury. The mechanism involved includes multi-target effects by modulating various synergistic pathways that control oxidative stress, inflammation, mitochondria, autophagy, and cell death, as well as AMPK signaling that is associated with possible beneficial effects on metabolic disorders. However, evidence-based data supporting the effectiveness of Rhodiola or salidroside in treating metabolic disorders is limited. Therefore, a comprehensive review of available trials showing putative treatment strategies of metabolic disorders that include both clinical effective perspectives and fundamental molecular mechanisms is warranted. This review highlights studies that focus on the potential role of Rhodiola extracts and salidroside in type 2 diabetes and atherosclerosis, the two most common metabolic diseases.
在过去的三十年中，人们对支持红景天在应激和与衰老相关的疾病中潜在用途的机制的了解有所增加，并为专注于红景天在预防或治疗代谢疾病中的应用的研究提供了通用框架。特别引人关注的是红景天在维持能量平衡方面的新兴作用。此外，在过去的二十年中，人们做出了巨大的努力来揭示红景天在治疗代谢紊乱中的作用机制。红景天提取物和红景天苷（红景天中最丰富的活性化合物）被认为对精神、行为和代谢紊乱具有有益的作用。体内和体外研究都表明，红景天提取物和红景天苷在急性或实验性损伤前给药时可以改善代谢紊乱。所涉及的机制包括通过调节控制氧化应激、炎症、线粒体、自噬和细胞死亡的各种协同途径以及与代谢紊乱的可能有益作用相关的 AMPK 信号转导的多靶点效应。然而，支持红景天或红景天苷治疗代谢紊乱有效性的基于证据的数据有限。因此，有必要对现有的试验进行全面审查，这些试验显示出包括临床有效观点和基本分子机制在内的代谢紊乱的潜在治疗策略。本综述重点介绍了关注红景天提取物和红景天苷在 2 型糖尿病和动脉粥样硬化这两种最常见的代谢疾病中潜在作用的研究。
